Incyte Receives Positive CHMP Opinion for Opzelura® Cream in Adults with Moderate Atopic Dermatitis Incyte has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
CHMP Recommends EU Approval of DAYBUE® (trofinetide) Acadia Pharmaceuticals Inc. has announced a significant regulatory milestone for its rare disease portfolio after the Committee for Medicinal Products for Human Use…
Stallergenes Greer Earns 2026 Switzerland’s Best Managed Companies Award for Excellence in Leadership, Innovation, and Sustainable Growth Stallergenes Greer, a global leader in allergy immunotherapy and allergy care, has been…
MaaT Pharma to Seek EMA Re-Examination After CHMP Issues Negative Opinion on Conditional Marketing Application for Xervyteg® in Acute Graft-versus-Host Disease Clinical-stage biotechnology company MaaT Pharma has announced that the…
FIRST Survey Highlights the Emotional, Social, and Daily Challenges Faced by People Living with Ichthyosis, Reinforcing the Need for Better Treatments and Support The Foundation for Ichthyosis & Related Skin…
MRM Health Strengthens Board of Directors with Two Industry Veterans as Lead Microbiome Therapy Advances Toward Late-Stage Development MRM Health, a clinical-stage biotechnology company focused on developing microbiome-based therapeutics for…
Elevation Spine Surpasses 5,000 Saber-C Implantations, Highlighting Growing Adoption of Its Integrated Cervical Fusion Technology Elevation Spine has announced a significant milestone for its cervical spine portfolio, revealing that more…
Trodelvy® is now FDA-approved as a first-line treatment option for patients with metastatic triple-negative breast cancer, expanding its role in frontline care. Gilead Sciences has secured a major new U.S.…
Carnegie Mellon-Led Team Secures Up to $39.3 Million ARPA-H Award to Develop OMEGA Fetal Monitoring System Carnegie Mellon University is spearheading a major multi-institution research initiative aimed at transforming how…
TRYNGOLZA® becomes the first and only FDA-approved treatment for severe hypertriglyceridemia, reducing both triglyceride levels and the risk of acute pancreatitis. Ionis Pharmaceuticals has secured a major regulatory milestone with…
Pfizer’s IBRANCE Wins FDA Approval in HR+/HER2+ Metastatic Breast Cancer, Expanding CDK4/6 Use Into New Maintenance Setting Pfizer has secured a significant new U.S. regulatory milestone for IBRANCE (palbociclib), with…
AL-S Pharma Presents Phase 2 AP-101 Data at ENCALS 2026, Highlighting Potential Disease-Modifying Effects in ALS AL-S Pharma AG, a clinical-stage biotechnology company focused on developing antibody therapies against misfolded…